Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

Justin M. Watts, MD
Five-Year Follow-Up Data Confirm Long-Term Benefits of Olutasidenib in R/R IDH1+ AML

July 22nd 2024

Justin M. Watts, MD, discusses 5-year efficacy and safety data for olutasidenib in IDH1-mutant, relapsed/refractory AML.

The FDA has granted fast track designation to CT-0525 for the treatment of patients with HER2-overexpressing solid tumors.
FDA Awards Fast Track Designation to CT-0525 for HER2-Overexpressing Solid Tumors

July 14th 2024

Vivek Subbiah, MD, chief, early-phase drug development, Sarah Cannon Research Institute
Dual Targeting of the mTOR Pathway May Enhance Antitumor Activity in Solid Malignancies

July 11th 2024

FDA
OncLive’s June Roundup of Key FDA Approvals in Oncology

July 3rd 2024

FDA
FDA Green Lights Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

July 1st 2024

More News